



## **BioNTech to Host First Edition of Innovation Series on Diversified Pipeline, Latest Technology Innovations**

June 20, 2022

**MAINZ, Germany, June 20, 2022 (GLOBE NEWSWIRE)** -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or the "Company") will host the first edition of the Company's Innovation Series on Wednesday, June 29<sup>th</sup>, 2022. The virtual event will provide an update on BioNTech's clinical progress across its pipeline and provide a deep-dive on scientific and technology innovation from its proprietary research engine.

Investors and the interested public are invited to join a webcast with investment analysts at 8:00 a.m. EDT (2:00 p.m. CEST). Online participation will be listen-only. To listen to the webcast, you will first need to register at the following [link](#). You will then be able to access the slide presentation and audio of the webcast via this [link](#) and log in using the same email address you used to register. The platform will open ten minutes prior to the start of the event.

A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.

### **About BioNTech**

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit [www.BioNTech.de](http://www.BioNTech.de).

### **CONTACTS**

#### **Investor Relations**

Sylke Maas, Ph.D.  
VP Investor Relations & Strategy  
Tel: +49 (0)6131 9084 1074  
E-mail: [investors@biontech.de](mailto:investors@biontech.de)

#### **Media Relations**

Jasmina Alatovic  
VP Corporate Communications  
Tel: +49 (0)6131 9084 1513  
E-mail: [Media@biontech.de](mailto:Media@biontech.de)